Laurus Labs Ltd (LAURUSLABS)

Laurus Labs Sees Upside as Analysts Upgrade Rating and Company Reports Sequential Uptick in Q4FY24 - 29 Apr, 2024

Laurus Labs is set to see an increase in its stock price after KR Choksey upgraded the company's rating from Accumulate to Buy, citing improved margins over FY25E-FY26E. The company also reported a sequential uptick in both top line and margins in Q4FY24, while analysts expect strong growth over the next few years.

Laurus Labs to Pay Dividend, Yield at 0.2% - 28 Apr, 2024

Laurus Labs Limited will pay a dividend of ₹0.40 per share on August 10th, with a yield of 0.2%. While EPS growth is positive, the low payout ratio and negative free cash flows make relying on this stock for dividend income risky.

Mixed Results for Laurus Labs in Q4 and FY2024 Earnings Reports - 27 Apr, 2024

Laurus Labs' Q4 results show strong revenue growth but a decline in net income compared to the previous year. The company's FY2024 earnings report reveals an 80% YoY drop in net income and an EPS that missed analyst estimates by 17%. Despite this, the company is forecasted to see steady revenue growth over the next three years.

Mixed Analyst Views on Laurus Labs' Future Prospects - 26 Apr, 2024

Laurus Labs reports better-than-expected revenue in Q4FY24, but Jefferies maintains an underperform rating due to weak CDMO performance. Motilal Oswal has a buy call with a target price of Rs 480, while analysts note that CDMO services are key to improved prospects, but delays in crucial projects and lack of visibility on commercial contracts remain concerns.

Laurus Labs' Q4FY24 Net Profit Falls 25% - 25 Apr, 2024

Laurus Labs reports a decline in net profit by 25% YoY in the March quarter, while revenue rose by 4%. The company's EBITDA margin was at 16.7%, missing expectations. Laurus Labs declared an interim dividend of Rs 0.40 per share.

Laurus Labs' API Manufacturing Facility Clears USFDA Inspection - 22 Apr, 2024

Laurus Labs announced that its API manufacturing facility located in Parawada, Anakapalli (Vishakapatnam), Andhra Pradesh has cleared the US Food and Drug Administration (USFDA) inspection with zero observations.

Laurus Labs' API Manufacturing Facility Clears USFDA Inspection - 20 Apr, 2024

Laurus Labs' API manufacturing facility in Andhra Pradesh has cleared the USFDA inspection with zero observations. The company specializes in generic APIs and anti-retroviral, oncology, cardiovascular, gastro, and hepatitis C therapeutics.

Laurus Labs Among Top Picks by Axis Securities Expert - 18 Apr, 2024

Rajesh Palviya, Head Technical Research at Axis Securities, has selected Laurus Labs Ltd as one of his top picks for the day. The stock is expected to reach a target of Rs 455-460 with a stop loss of Rs 436.

Mitessh Thakkar Recommends Buy Call on Laurus Labs - 15 Apr, 2024

Technical analyst Mitessh Thakkar recommends a buy call on Laurus Labs with an upside target of ₹1,720 and stop loss at ₹1,669. Shares have gained over 6% in the last month.

Goldman Sachs Initiates Sell Rating on Laurus Labs - 12 Apr, 2024

Laurus Labs is likely to see its shares fall as much as 23% over the next 12 months, according to Goldman Sachs. The brokerage initiated coverage on Laurus Labs with a sell recommendation and with a price target of ₹350.

Laurus Labs Undergoes Transformation to Become Integrated Pharma Company - 04 Apr, 2024

Laurus Labs shifts focus towards becoming an integrated pharma company with significant growth in the CDMO segment and a new biotech business through acquisition of Richcore Life Sciences. The stock is up 43.85% in the last year.

Laurus Labs Ltd Up 2.73% on NSE - 02 Apr, 2024

Laurus Labs Ltd is up 2.73% on the NSE, trading at Rs 416.3 as of 12:49 IST. The stock has seen a 36.65% increase in the last year compared to a 28.88% spurt in NIFTY and a 58.71% spurt in the Nifty Pharma index. The PE ratio based on TTM earnings ending December 23 is 103.09.

Laurus Labs Revenue Grows at 27% CAGR in Last Five Years - 01 Apr, 2024

Indian CDMO player, Laurus Labs, is expanding with a ₹990 crore investment. The company has grown its revenues at a compound annual growth rate (CAGR) of 27% over the last five years, with 60% of revenue coming from US and European customers.